Strategic partnerships Leverage WhiteLab Genomics’ ongoing collaborations with Debiopharm, Sanofi, Cytiva, and Siren Biotechnology to identify co-selling, joint development, or referral opportunities that expand into oncology, neurology, and rare diseases.

AI Platform Upsell Position the AI-driven platform as a supplier of design and optimization capabilities for delivery vectors and payloads to mid-to-large pharma and CROs seeking faster preclinical cycle times and safer therapies.

Geographic Expansion Target potential partners in Paris, Boston, and Montréal ecosystems where WLG already operates, focusing on biotech clusters, academic collaborations, and contract research needs to accelerate local engagements.

Clinical pipeline alignment Map WhiteLab’s capabilities to clients’ therapeutic areas such as oncology, neurology, ophthalmology, and rare diseases to propose AI-enabled indication discovery, design optimization, and rapid preclinical validation services.

Funding and governance leverage Highlight recent funding and high-profile board connections (including former Sanofi executive) to prospects as proof of credibility and potential for co-development partnerships, grant-funded projects, or strategic investments.